(Q42536248)

1 November 2017

title

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses (English)

1 reference

1 November 2017

1 reference

1 reference

D P Tashkin

1

1 reference

1 November 2017

R A Nathan

2

1 reference

1 November 2017

W C Howland

3

1 reference

1 November 2017

M C Minkwitz

4

1 reference

1 November 2017

S G Simonson

5

1 reference

1 November 2017

C M Bonuccelli

6

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

The Journal of Allergy and Clinical Immunology

1 November 2017

published in

1 reference

1 November 2017

volume

103

1 reference

1 November 2017

issue

2 Pt 1

1 reference

1 November 2017

page(s)

246-254

1 reference

Leukotriene activity modulation in asthma

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Anti-leukotriene agents: a new direction in asthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Statistical problems in the reporting of clinical trials. A survey of three medical journals.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

A consumer's guide to subgroup analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Race, income, urbanicity, and asthma hospitalization in California: a small area analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Asthma among Puerto Rican Hispanics: a multi-ethnic comparison study of risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Ethnic differences in the prevalence of asthma in middle class children.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

The distribution of peak expiratory flow variability in a population sample

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

The normal range of diurnal changes in peak expiratory flow rates. Relationship to symptoms and respiratory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

Peak flow lability: association with asthma and spirometry in an older cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970498-7

7 January 2021

10.1016/S0091-6749(99)70498-7

Identifiers

DOI

1 reference

1 November 2017

1 reference